NAGE
Niagen Bioscience, Inc.
2.80$
+4.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 88.2% | 90.1% | 90.6% | 91.2% | 92.2% | 93.9% | 93.7% | 94.7% | 95.4% | 91.0% | 91.9% | 91.7% | |
| 49.8% | 49.4% | 50.7% | 51.3% | 57.1% | 65.2% | 68.2% | 65.9% | 65.4% | 60.9% | 58.2% | 62.6% | |
| 49.8% | 49.4% | 50.7% | 51.3% | 57.1% | 65.2% | 68.2% | 65.9% | 65.4% | 60.9% | 58.2% | 62.6% | |
| 10.5% | 9.5% | 12.2% | 14.5% | 12.6% | 11.4% | 8.7% | 10.6% | 8.7% | 9.2% | 11.4% | 8.0% | |
| 23.6% | 26.4% | 23.1% | 21.3% | 18.7% | 13.5% | 13.8% | 15.7% | 19.1% | 19.2% | 21.0% | 19.4% | |
| 1.0% | 0.9% | 0.9% | 0.8% | 0.7% | 0.5% | 0.4% | 0.3% | 0.3% | 5.3% | 4.8% | 5.0% | |
| 48.9% | 48.2% | 46.5% | 43.2% | 39.2% | 32.5% | 32.0% | 29.9% | 28.0% | 28.1% | 28.0% | 22.6% | |
| 36.4% | 37.5% | 36.0% | 33.1% | 31.3% | 26.3% | 25.6% | 24.4% | 23.1% | 18.7% | 20.0% | 14.1% | |
| 1.6% | 1.3% | 1.6% | 1.8% | 1.8% | 1.5% | 1.2% | 1.1% | 1.0% | 0.9% | 0.9% | 0.9% | |
| 17.2% | 18.6% | 14.6% | 15.0% | 12.2% | 12.5% | 13.1% | 14.9% | 13.0% | 10.1% | 11.6% | 8.9% | |
| 51.1% | 51.8% | 53.5% | 56.8% | 60.8% | 67.5% | 68.0% | 70.1% | 72.0% | 71.9% | 72.0% | 77.4% | |
| -356.3% | -346.5% | -353.1% | -353.4% | -334.5% | -266.4% | -217.4% | -189.3% | -171.9% | -154.6% | -138.4% | -147.5% | |
| 140.3% | 136.6% | 139.1% | 139.8% | 137.6% | 119.6% | 102.3% | 94.2% | 88.3% | 79.4% | 74.0% | 77.4% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.